Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Change in Cash (2016 - 2025)

Historic Change in Cash for CorMedix (CRMD) over the last 13 years, with Q3 2025 value amounting to -$109.9 million.

  • CorMedix's Change in Cash fell 172955.95% to -$109.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year increase of 15355.42%. This contributed to the annual value of -$3.1 million for FY2024, which is 78392.79% down from last year.
  • Per CorMedix's latest filing, its Change in Cash stood at -$109.9 million for Q3 2025, which was down 172955.95% from $93.0 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Change in Cash ranged from a high of $93.0 million in Q2 2025 and a low of -$109.9 million during Q3 2025
  • Its 5-year average for Change in Cash is -$683870.1, with a median of -$4.4 million in 2021.
  • Over the last 5 years, CorMedix's Change in Cash had its largest YoY gain of 148533.39% in 2025, and its largest YoY loss of 172955.95% in 2025.
  • CorMedix's Change in Cash (Quarter) stood at -$13.0 million in 2021, then surged by 99.27% to -$95334.0 in 2022, then plummeted by 18653.02% to -$17.9 million in 2023, then soared by 130.01% to $5.4 million in 2024, then tumbled by 2149.1% to -$109.9 million in 2025.
  • Its Change in Cash was -$109.9 million in Q3 2025, compared to $93.0 million in Q2 2025 and $25.6 million in Q1 2025.